This guide offers an educational, technical overview of coronary artery disease & cardiac interventions and the device technologies used in this field. Coronary artery disease develops when atherosclerotic plaque accumulates within the arteries that supply the heart muscle, gradually narrowing the lumen and limiting blood flow. As a medical device manufacturer, INVAMED develops technologies in this area; the information here is educational and not medical advice.
Background: Coronary Artery Disease and Percutaneous Coronary Intervention
During PCI a lesion is usually crossed with a guidewire, prepared with a balloon, and in most cases scaffolded with a stent that holds the vessel open. The specific combination of wires, balloons, atherectomy, and stents is determined by the interventional cardiologist based on lesion complexity, calcification, and overall clinical picture. When a narrowing becomes flow-limiting, patients may experience angina on exertion, and an abrupt plaque rupture with thrombosis can precipitate a myocardial infarction.
Core Technologies and Options
Drug-Eluting Stent (DES) Technology. A drug-eluting stent combines a thin metallic scaffold with a polymer coating that releases an antiproliferative drug into the vessel wall over time. The eluted drug is intended to suppress the neointimal hyperplasia that drives in-stent restenosis after a bare scaffold is placed. Sirolimus-Eluting Stent Platform. Sirolimus is a widely used antiproliferative agent that interrupts the cell-cycle signaling responsible for excessive tissue growth inside a stent. Delivering sirolimus locally from the stent surface concentrates the drug at the treated segment while limiting systemic exposure. Cobalt-Chromium and Stainless-Steel Stent Options. Coronary stents are offered on different alloy platforms, with cobalt-chromium and stainless steel being common choices that trade off strut thickness against strength. Cobalt-chromium allows thinner struts for a given radial strength, which is generally associated with lower profile delivery and favorable healing. PTCA and Drug-Eluting Balloon Catheters. A percutaneous transluminal coronary angioplasty (PTCA) balloon dilates a stenosis to prepare the lesion or to treat it without leaving a permanent implant. A drug-eluting balloon adds an antiproliferative coating that transfers to the vessel wall during inflation, which can be useful for in-stent restenosis or small-vessel disease. Coronary Rotational Atherectomy. Rotational atherectomy modifies heavily calcified plaque so that balloons and stents can be delivered and expanded adequately. A high-speed burr selectively ablates hard, inelastic calcium while the technique is designed to spare more elastic tissue. Guide Extension and Support Catheters. Guide extension catheters telescope through a guiding catheter to provide deep-vessel backup support during complex or tortuous PCI. This added support can improve device delivery when a lesion is distal, calcified, or difficult to reach.
Comparing the Approaches
Drug-eluting stent vs Bare-metal stent. Drug-eluting and bare-metal stents both scaffold the artery, but only the drug-eluting version releases an antiproliferative agent to limit restenosis. Modern thin-strut drug-eluting designs, such as INVAMED's cobalt-chromium ATLAS DES, aim to combine strong scaffolding with favorable healing. PCI (stenting) vs Bypass surgery (CABG). Percutaneous coronary intervention treats a lesion from inside the artery with a catheter, while coronary artery bypass grafting surgically routes blood around blockages. Contemporary decision-making frequently uses a heart-team discussion and anatomic complexity scoring to weigh the two. Balloon angioplasty alone vs Angioplasty with stenting. Balloon angioplasty alone can open a lesion but leaves the vessel prone to recoil or dissection, whereas adding a stent secures a durable lumen. Stenting, especially with a drug-eluting platform, has become the default for most obstructive coronary lesions.
INVAMED Portfolio in This Area
INVAMED's related devices include: ATLAS Drug Eluting Coronary Stent System Cobalt Chromium, Atlas Coronary Stent System Cobalt Chromium, Atlas Coronary Stent System Stainless Steel, Extender Drug Eluting PTCA Balloon Catheter, Inwire PTCA Guidewire, TemREN Rotablator, AngioTEN Vascular Closure System. Detailed specifications for each are provided in the product documentation.
Key Considerations
- Thin-strut cobalt-chromium platforms are intended to balance deliverability with radial support in a range of vessel sizes.
- Dual antiplatelet therapy duration is individualized to the clinical presentation and the patient's bleeding risk.
- All INVAMED coronary devices are intended for use by trained interventional cardiologists under fluoroscopic guidance and per the IFU.
Frequently Asked Questions
What drug does the ATLAS stent release?
According to INVAMED, the ATLAS DES elutes sirolimus at 1 microgram per square millimeter with a sustained controlled-release profile.
What is the reported restenosis performance of the ATLAS DES?
INVAMED reports clinical data showing target lesion revascularization rates below 5% at 12 months; this reflects studied performance and is not an individual guarantee.
Does INVAMED make a drug-coated coronary balloon?
Yes. The Extender Drug Eluting PTCA Balloon Catheter carries a paclitaxel coating for local drug delivery, such as in-stent restenosis or small-vessel disease.
About INVAMED
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.
Related on INVAMED
- Coronary Artery Disease & Cardiac Interventions — product category
- Atlas Coronary Stent System Stainless Steel: Features, Specifications and Clinical Role
- Arterial Access Closure: How It Works and Why It Matters
- Coronary Rotational Atherectomy: Technology, Uses and Considerations
Important Disclaimer
The information here is provided for educational purposes and to describe device technology; it is not a substitute for professional medical advice, diagnosis, or treatment. Only a licensed healthcare provider can determine whether a given procedure or device is appropriate for a specific patient. INVAMED products are restricted to use by qualified professionals following the official IFU. Regulatory clearance and labeling differ between regions, and not all products or indications are available in every market.
Reviewed by the INVAMED Medical Affairs team. Content is educational and technical in nature.